89bio, Inc.

NasdaqGM ETNB

89bio, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -119,507.69%

89bio, Inc. EBITDA Margin is -119,507.69% for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGM: ETNB

89bio, Inc.

CEO	Mr. Rohan Palekar
IPO Date	Nov. 11, 2019
Location	United States
Headquarters	142 Sansome Street
Employees	70
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Key trends

Past 5 years